[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know",
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $220.18, representing a -3.98% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=b26102e17577f23767bb7ab80b1ccec33745aa881c24a15a15c7976a0daede0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767653104,
      "headline": "AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know",
      "id": 137997694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The latest trading day saw AbbVie (ABBV) settling at $220.18, representing a -3.98% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=b26102e17577f23767bb7ab80b1ccec33745aa881c24a15a15c7976a0daede0c"
    }
  },
  {
    "ts": null,
    "headline": "Biotech and Pharma Stocks Tumble as Investors Race into Energy",
    "summary": "Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.",
    "url": "https://finnhub.io/api/news?id=28a81daf1c3ad74136be78f734ee45654c1db7bb4e799156d35e55a1db347bb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767639120,
      "headline": "Biotech and Pharma Stocks Tumble as Investors Race into Energy",
      "id": 137997667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.",
      "url": "https://finnhub.io/api/news?id=28a81daf1c3ad74136be78f734ee45654c1db7bb4e799156d35e55a1db347bb4"
    }
  },
  {
    "ts": null,
    "headline": "Assessing AbbVie (ABBV) Valuation After Strong Multi‑Year Shareholder Returns",
    "summary": "AbbVie (ABBV) has been drawing fresh attention after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months as investors reassess its large biopharma portfolio. See our latest analysis for AbbVie. At a share price of US$229.31, AbbVie’s short term share price returns have been fairly muted, while its 1 year total shareholder return of 31.78% and 5 year total shareholder return of 155.61% point to sustained investor interest. Earlier...",
    "url": "https://finnhub.io/api/news?id=a0d535560ab7ecb4ebb260e5cba5c6d916c68fce509cc5af557cc3139e208a2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767632947,
      "headline": "Assessing AbbVie (ABBV) Valuation After Strong Multi‑Year Shareholder Returns",
      "id": 137992848,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has been drawing fresh attention after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months as investors reassess its large biopharma portfolio. See our latest analysis for AbbVie. At a share price of US$229.31, AbbVie’s short term share price returns have been fairly muted, while its 1 year total shareholder return of 31.78% and 5 year total shareholder return of 155.61% point to sustained investor interest. Earlier...",
      "url": "https://finnhub.io/api/news?id=a0d535560ab7ecb4ebb260e5cba5c6d916c68fce509cc5af557cc3139e208a2e"
    }
  },
  {
    "ts": null,
    "headline": "The Tiny $1.3b High Yield ETF That Retirees Should Consider Now | DHS",
    "summary": "The WisdomTree U.S. High Dividend Fund (NYSEARCA:DHS) offers retirees monthly income and capital appreciation. With $1.3 billion in assets and a 3.46% yield, this ETF holds diversified high-dividend U.S. equities. The fund’s defensive tilt (41% in consumer staples, healthcare, and utilities) provides stability, while its 0.38% expense ratio keeps costs low. DHS delivers monthly distributions, ... The Tiny $1.3b High Yield ETF That Retirees Should Consider Now | DHS",
    "url": "https://finnhub.io/api/news?id=c8eeb9b084c61906c1e9c22c2255be1235fe9979ad4753082dc77fef81de605c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767627196,
      "headline": "The Tiny $1.3b High Yield ETF That Retirees Should Consider Now | DHS",
      "id": 137992414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The WisdomTree U.S. High Dividend Fund (NYSEARCA:DHS) offers retirees monthly income and capital appreciation. With $1.3 billion in assets and a 3.46% yield, this ETF holds diversified high-dividend U.S. equities. The fund’s defensive tilt (41% in consumer staples, healthcare, and utilities) provides stability, while its 0.38% expense ratio keeps costs low. DHS delivers monthly distributions, ... The Tiny $1.3b High Yield ETF That Retirees Should Consider Now | DHS",
      "url": "https://finnhub.io/api/news?id=c8eeb9b084c61906c1e9c22c2255be1235fe9979ad4753082dc77fef81de605c"
    }
  },
  {
    "ts": null,
    "headline": "AI took investors on a date in 2025. In 2026, analysts say it's time to foot the bill.",
    "summary": "As the AI trade becomes \"fractured,\" 2026 could see other stocks finally outshine the \"Magnificent Seven.\"",
    "url": "https://finnhub.io/api/news?id=8bc5645a656abb8f8ecdca3b915a1c7c67b2fa5e37d8aa133dbeb5a3e90263f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767621612,
      "headline": "AI took investors on a date in 2025. In 2026, analysts say it's time to foot the bill.",
      "id": 137990801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the AI trade becomes \"fractured,\" 2026 could see other stocks finally outshine the \"Magnificent Seven.\"",
      "url": "https://finnhub.io/api/news?id=8bc5645a656abb8f8ecdca3b915a1c7c67b2fa5e37d8aa133dbeb5a3e90263f8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.",
    "url": "https://finnhub.io/api/news?id=9032154fbe914b96b6c61543082b85edbcf42930c264a9a6cd1e28c940497c4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767618000,
      "headline": "AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 137990956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.",
      "url": "https://finnhub.io/api/news?id=9032154fbe914b96b6c61543082b85edbcf42930c264a9a6cd1e28c940497c4e"
    }
  },
  {
    "ts": null,
    "headline": "Rosacea Market Research and Forecast Report 2025-2035: Expansion Driven by Regulatory Approval of Novel Therapies Such as Emrosi and Rhofade and Rapid Adoption of Teledermatology Platforms",
    "summary": "Rosacea is a chronic skin condition that presents as facial redness, visible blood vessels, and acne-like bumps, affecting the face, neck, chest, and eyes. The global rosacea market is experiencing growth propelled by increasing cases in adults aged 30-60, expanded awareness, and newly approved treatments like Emrosi and Rhofade. Barriers such as high medication costs and underdiagnosis in darker skin tones remain. However, innovative therapies, the rise of teledermatology, and personalized skin",
    "url": "https://finnhub.io/api/news?id=ca2f6276affb2c76913d98578de6fa6eef94a02907f51f90351ada0cc57fff8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767604260,
      "headline": "Rosacea Market Research and Forecast Report 2025-2035: Expansion Driven by Regulatory Approval of Novel Therapies Such as Emrosi and Rhofade and Rapid Adoption of Teledermatology Platforms",
      "id": 137991052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Rosacea is a chronic skin condition that presents as facial redness, visible blood vessels, and acne-like bumps, affecting the face, neck, chest, and eyes. The global rosacea market is experiencing growth propelled by increasing cases in adults aged 30-60, expanded awareness, and newly approved treatments like Emrosi and Rhofade. Barriers such as high medication costs and underdiagnosis in darker skin tones remain. However, innovative therapies, the rise of teledermatology, and personalized skin",
      "url": "https://finnhub.io/api/news?id=ca2f6276affb2c76913d98578de6fa6eef94a02907f51f90351ada0cc57fff8b"
    }
  }
]